文献速递生殖医学

科菲立曲普α用于体外受精卵巢刺激:随机对照试验的系统评价与Meta分析

Corifollitropin alfa for ovarian stimulation in in vitro fertilization: a systematic review and meta-analysis of randomized controlled trials.
PubMed 文献 · Fertil Steril · 2019-01-01

该系统评价与Meta分析纳入8项随机对照试验、共4,340个IVF周期(干预组2,345例,对照组1,995例),比较科菲立曲普α与每日注射的常规卵巢刺激方案。两组活产率和/或持续妊娠率无显著差异(RR 0.92,95%CI 0.80-1.05),临床妊娠率、流产率、多胎妊娠率及周期取消、卵巢过度刺激综合征、异位妊娠率亦相似。作者认为,科菲立曲普α似乎可作为正常反应与低反应患者每日重组FSH注射的替代方案。

要点

  • 8项随机对照试验、4,340个IVF周期显示,科菲立曲普α与每日注射方案的活产率和/或持续妊娠率无显著差异(RR 0.92,95%CI 0.80-1.05)。
  • 临床妊娠率(RR 0.96,95%CI 0.88-1.05)、流产率(RR 0.94,95%CI 0.71-1.25)、多胎妊娠率(RR 1.22,95%CI 0.99-1.50)两组均无显著差异。
  • 周期取消率、卵巢过度刺激综合征率和异位妊娠率两组相似;作者认为科菲立曲普α似乎可作为正常和低反应患者每日重组FSH注射的替代。

核心结论

  • 科菲立曲普α似乎是正常反应和低反应患者接受IVF/ICSI卵巢刺激时每日重组FSH注射的一种替代方案。

研究设计与样本

  • 系统评价与Meta分析,纳入8项随机对照试验,干预组2,345例、对照组1,995例,共分析4,340个IVF周期;方案已在PROSPERO注册(CRD42018088605)。

主要发现

  • 活产率和/或持续妊娠率两组无差异(RR 0.92,95%CI 0.80-1.05)。
  • 临床妊娠率无差异(RR 0.96,95%CI 0.88-1.05;I²=0%)。
  • 流产率无差异(RR 0.94,95%CI 0.71-1.25;I²=0%)。
  • 多胎妊娠率无差异(RR 1.22,95%CI 0.99-1.50;I²=0%)。
  • 周期取消率、卵巢过度刺激综合征率和异位妊娠率两组相似;敏感性和亚组分析未使合并结果发生统计学改变。

临床怎么用

  • 作者认为,科菲立曲普α似乎可作为正常反应和低反应患者在IVF/ICSI卵巢刺激中每日重组FSH注射的替代方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the effectiveness of corifollitropin alfa in improving the success of IVF. DESIGN: Systematic review and meta-analysis. SETTING: Not applicable. PATIENT(S): Infertile women undergoing conventional IVF or intracytoplasmic sperm injection (ICSI). INTERVENTION(S): Randomized controlled trials (RCTs) of infertile women undergoing a single IVF/ICSI cycle with either corifollitropin alfa or a conventional ovarian stimulation protocol based on daily injections. The review protocol was registered in PROSPERO before starting the data extraction (CRD42018088605). MAIN OUTCOME MEASURE(S): Primary outcomes were live birth rate and/or ongoing pregnancy rate. Clinical pregnancy rate, miscarriage rate, multiple pregnancies, number of oocytes and embryos obtained, cancellation rate, and rate of ovarian hyperstimulation syndrome and ectopic pregnancy were considered as secondary outcomes. RESULT(S): Eight randomized controlled trials were included; 2,345 women were assigned to the intervention group and 1,995 to the control group. The analysis of 4,340 IVF cycles did not reveal any difference in live birth rate and/or ongoing pregnancy rate between groups (risk ratio [RR], 0.92; 95% confidence interval [CI], 0.80-1.05). Similarly, no difference was found in clinical pregnancy rate (RR, 0.96; 95% CI, 0.88-1.05; I2 = 0%), miscarriage rate (RR, 0.94; 95% CI, 0.71-1.25; I2 = 0%), or multiple pregnancy rate (RR, 1.22; 95% CI, 0.99-1.50; I2 = 0%). Also, the rates of cycle cancellation, ovarian hyperstimulation syndrome, and ectopic pregnancy were similar in both groups. Sensitivity and subgroup analyses did not provide statistical changes to pooled results. CONCLUSION(S): Corifollitropin alfa seems to be an alternative for daily recombinant FSH injections in normal and poor responder patients undergoing ovarian stimulation in IVF/ICSI treatment cycles.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Cozzolino M, Vitagliano A, Cecchino GN, et al. Corifollitropin alfa for ovarian stimulation in in vitro fertilization: a systematic review and meta-analysis of randomized controlled trials. Fertil Steril. 2019. PMID: 30929731. doi:10.1016/j.fertnstert.2018.11.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。